A study on druggability of MIA as a promising approach for inhibition of metastasis
by Jamal Shamsara
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 7, No. 1, 2014

Abstract: MIA (Melanoma Inhibitory Activity) protein is over expressed in melanoma cells and binds to extracellular matrix proteins as well as to several integrins. These interactions were suggested to promote formation of metastasis. Therefore, abrogation of MIA interaction with other proteins using small molecules might show a diminishing effect on cancer cell invasion. The present study is aimed at the analysis of the integrin-binding site of MIA using molecular docking, followed by a virtual screening for drug-like compounds that show potential as putative inhibitors of MIA-integrin interaction. Results showed that at the proposed binding interface of the MIA-integrin complex, a druggable binding pocket is located. Therefore, the integrin-binding domain of MIA was used as a receptor to screen 2200 drug-like compounds. Next, we analysed the interactions of the identified hit compounds with the MIA binding pocket to find the most important features of the hit compounds.

Online publication date: Tue, 21-Oct-2014

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?


Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com